The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)

Completed

You are on the General Public view
  • Source

    -
    Public Title The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00357812
  • Trial

    -
    Health Condition(s) or Problem Herpes Simplex Keratitis
    Lay Summary The aim of this study is to compare the safety, specificity, sensitivity and ease of procedure of two potential diagnostic assays for HSV-1 detection in the cornea. Through the use of this new diagnostic assay, correct and early intervention would not only reduce corneal scarring from HSK, but it would also allow the initiation of appropriate treatment for HSV mimicking keratitis. HSV-1 infection of the eye can result in corneal scarring and blindness. Early diagnosis of this condition and appropriate treatment is of utmost importance. Various ocular surface conditions can mimic herpetic keratitis in their clinical presentation and can result in diagnostic confusion. Inappropriate or delayed treatment of herpetic corneal disease results in increased morbidity. In the UK at present clinical presentation is the mainstay of diagnosis. Unfortunately these cases often present to the most inexperienced clinical staff resulting in variability in diagnostic acumen. This often results in a delay or inappropriate diagnosis of herpetic keratitis. Laboratory techniques presently available to aid diagnosis are infrequently used in clinical practice. There are various reasons for their lack of use. Historically viral culture techniques were the mainstay of investigation but were slow, requiring weeks to provide a result. PCR is now replacing culture techniques and is relatively quick, reliable and sensitive. Many clinicians within the UK are still not fully informed of these advances and are therefore not utilizing these techniques to supplement clinical diagnosis. We propose to investigate the use of topically applied fluorescent antibody against active replicating HSV-1 in a droplet form and real time PCR detection of the virus. If successful this should increase the potential diagnostic capabilities of GPs and other less experienced health care workers. Such tests should reduce variability in diagnosis and the dependency on experienced ophthalmologists to diagnose the condition. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: Patients over the age of 16 years in which the cause of keratitis is difficult to diagnose and in which HSK has to be excluded will be enrolled for this study Exclusion Criteria: Immunosuppressed patients including patients treated with systemic steroids will be excluded
    Who cannot enter the trial Inclusion Criteria: Patients over the age of 16 years in which the cause of keratitis is difficult to diagnose and in which HSK has to be excluded will be enrolled for this study Exclusion Criteria: Immunosuppressed patients including patients treated with systemic steroids will be excluded
    What will happen Sorry, not currently available
    Primary aim Sorry, not currently available
    Secondary Aim Sorry, not currently available
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Completed
    Nation England, Northern Ireland
    Location Birmingham, Bedford, Belfast
  • Contact

    -
    Contact for Public Queries Tara Moore, PhD Principal Investigator Department of Biomedical Sciences, University of Ulster
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.